ATM kinase is a master switch for the ΔNp63α phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage

We previously found that the pro-apoptotic DNA damaging agent, cisplatin, mediated the proteasome-dependent degradation of DeltaNp63alpha associated with its increased phosphorylated status. Since DeltaNp63alpha usually plays an opposite role to p53 and TAp63 in human cancers, we tested the notion that phosphorylation events induced by DNA damage would affect the protein degradation of DeltaNp63alpha in HNSCC cells upon cisplatin exposure. We found that DeltaNp63alpha is phosphorylated in the time-dependent fashion at the following positions: S385, T397, and S466, which were surrounded by recognition motifs for ATM, CDK2 and p70s6K kinases, respectively. We showed that chemical agents or siRNA inhibiting the activity of ATM, CDK2 and p70s6K kinases blocked degradation of DeltaNp63alpha in HNSCC cells after cisplatin exposure. Site-specific mutagenesis of DeltaNp63alpha residues targeted for phosphorylation by ATM, CDK2 or p70s6k led to dramatic modulation of DeltaNp63alpha degradation. Finally, we demonstrated that the DeltaNp63alpha protein is a target for direct in vitro phosphorylation by ATM, CDK2 or p70s6K. Our results implicate specific kinases, and target phosphorylation sites in the degradation of DeltaNp63alpha following DNA damage.

[1]  Ian M. Rosenberg,et al.  Protein Analysis and Purification , 1996, Birkhäuser Boston.

[2]  S. Nomoto,et al.  DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. , 2003, Cancer research.

[3]  Antonio Costanzo,et al.  A p38-dependent pathway regulates ΔNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes , 2005, Oncogene.

[4]  Zhongmin Guo,et al.  RACK1 and Stratifin Target ΔNp63α for a Proteasome Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage , 2004 .

[5]  L. Meijer,et al.  Cyclin dependent kinase inhibitors , 2003 .

[6]  D. Chan,et al.  Utilization of Oriented Peptide Libraries to Identify Substrate Motifs Selected by ATM* , 2000, The Journal of Biological Chemistry.

[7]  A. Mills,et al.  P63 Is an Essential Proapoptotic Protein during Neural Development , 2005, Neuron.

[8]  S. Nomoto,et al.  ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development , 2003 .

[9]  K. Tsai,et al.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage , 2002, Nature.

[10]  S. Carr,et al.  Mapping posttranslational modifications of proteins by MS-based selective detection: application to phosphoproteomics. , 2005, Methods in enzymology.

[11]  R. Pearson,et al.  Rapamycin, Wortmannin, and the Methylxanthine SQ20006 Inactivate p70s6k by Inducing Dephosphorylation of the Same Subset of Sites (*) , 1995, The Journal of Biological Chemistry.

[12]  R. Aebersold,et al.  A systematic approach to the analysis of protein phosphorylation , 2001, Nature Biotechnology.

[13]  T. Hupp,et al.  CK2-site Phosphorylation of p53 is Induced in ΔNp63 Expressing Basal Stem Cells in UVB Irradiated Human Skin , 2006, Cell cycle.

[14]  J. Pietenpol,et al.  Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. , 2005, Cell cycle.

[15]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[16]  Wei Cheng,et al.  ΔNp63 plays an anti-apoptotic role in ventral bladder development , 2006, Development.

[17]  B. Chait,et al.  Analysis of phosphorylated proteins and peptides by mass spectrometry. , 2001, Current opinion in chemical biology.

[18]  G. Melino,et al.  TAp63α induces apoptosis by activating signaling via death receptors and mitochondria , 2005, The EMBO journal.

[19]  A. Nussenzweig.  Causes and Consequences of the DNA Damage Response , 2007, Cell cycle.

[20]  G. Stark,et al.  Regulation of the G2/M transition by p53 , 2001, Oncogene.

[21]  A. Mills,et al.  p63, Cellular Senescence and Tumor Development , 2007, Cell cycle.

[22]  B. Trink,et al.  p53 associates with and targets Delta Np63 into a protein degradation pathway. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Rikiyama,et al.  p53 Homologue p63 Represses Epidermal Growth Factor Receptor Expression* , 2001, The Journal of Biological Chemistry.

[24]  D. Sidransky,et al.  DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. , 2005, Cell cycle.

[25]  P. Borst,et al.  How do real tumors become resistant to cisplatin? , 2008, Cell cycle.

[26]  T. Tokino,et al.  ΔNp63α functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes , 2003, Oncogene.

[27]  Zhongmin Guo,et al.  RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. , 2004, Cell cycle.

[28]  J. Yates,et al.  Probability-based validation of protein identifications using a modified SEQUEST algorithm. , 2002, Analytical chemistry.

[29]  R. Nelson,et al.  Mass spectrometry of the proteome. , 2001, Molecular pharmacology.

[30]  J. Shabanowitz,et al.  Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae , 2002, Nature Biotechnology.

[31]  G. Stark,et al.  Regulation of Ubiquitination and Degradation of p53 in Unstressed Cells through C-terminal Phosphorylation* , 2001, The Journal of Biological Chemistry.

[32]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[33]  S. Nomoto,et al.  ΔNp63 induces β-catenin nuclear accumulation and signaling , 2002 .

[34]  M. Wangpaichitr,et al.  Overcoming cisplatin resistance by mTOR inhibitor in lung cancer , 2005, Molecular Cancer.

[35]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[36]  R. Knight,et al.  TAp63 and ΔNp63 in Cancer and Epidermal Development , 2007 .

[37]  Yonghong Zhu.  A Model for CDK2 in Maintaining Genomic Stability , 2004, Cell cycle.

[38]  E. Appella,et al.  Post-translational modifications and activation of p53 by genotoxic stresses. , 2001, European journal of biochemistry.

[39]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[40]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[41]  S. Kato,et al.  The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. , 1999, Cancer research.

[42]  D. Sidransky,et al.  ΔNp63α Levels Correlate with Clinical Tumor Response to Cisplatin , 2005 .

[43]  J. Pietenpol,et al.  Ultraviolet Radiation Induces Phosphorylation and Ubiquitin-Mediated Degradation of ΔNP63α , 2005 .

[44]  D. Felsher,et al.  CDK2 Is Required By MYC to Induce Apoptosis , 2006, Cell cycle.

[45]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[46]  J. Funk,et al.  Linking DNA Damage to Cell Cycle Checkpoints , 2002, Cell cycle.

[47]  S. Nomoto,et al.  DeltaNp63 induces beta-catenin nuclear accumulation and signaling. , 2002, Cancer cell.

[48]  B. Trink,et al.  p63 and p73: teammates or adversaries? , 2006, Cancer cell.

[49]  T. Tokino,et al.  deltaNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. , 2003, Oncogene.

[50]  David Sidransky,et al.  p63 Transcriptional Regulation of Epithelial Integrity and Cancer , 2007, Cell cycle.

[51]  M. Lavin,et al.  ATM Activation and DNA Damage Response , 2007, Cell cycle.

[52]  J. Pietenpol,et al.  Transcriptional Programs Regulated by p63 in Normal Epithelium and Tumors , 2007, Cell cycle.

[53]  Gleevec Suppresses p63 Expression in Head and Neck Squamous Cell Carcinoma Despite p63 Activation by DNA‐Damaging Agents , 2006, The Laryngoscope.

[54]  E. Ratovitski,et al.  AEC-Associated p63 Mutations Lead to Alternative Splicing/Protein Stabilization of p63 and Modulation of Notch Signaling , 2005, Cell cycle.

[55]  Robert T. Abraham,et al.  Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase* , 2005, Journal of Biological Chemistry.

[56]  P. Allen,et al.  New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis , 2007, Apoptosis.

[57]  A. Chatterjee,et al.  U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha. , 2008, Cell cycle.

[58]  F. McKeon,et al.  Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. , 1999, The Journal of investigative dermatology.

[59]  Y. Ikawa,et al.  p51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation , 2000, Oncogene.

[60]  A. Fornace,et al.  Gadd45a regulates matrix metalloproteinases by suppressing DeltaNp63alpha and beta-catenin via p38 MAP kinase and APC complex activation. , 2004, Oncogene.

[61]  Jiri Bartek,et al.  ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks , 2006, Nature Cell Biology.

[62]  D. Sgroi,et al.  The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. , 2007, The Journal of clinical investigation.

[63]  S. Jackson,et al.  Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase , 2005, Nature Cell Biology.

[64]  K. Kihara,et al.  p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation. , 2002, Experimental cell research.

[65]  L. Ellisen,et al.  p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. , 2006, Cancer cell.

[66]  K. Vousden,et al.  Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.

[67]  T. Hunter,et al.  Protein kinase classification. , 1991, Methods in enzymology.

[68]  A. Yang,et al.  Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. , 2000, Cancer research.

[69]  E. Flores.  The Roles of p63 in Cancer , 2007, Cell cycle.

[70]  Frédérick A. Mallette,et al.  The DNA Damage Signaling Pathway Connects Oncogenic Stress to Cellular Senescence , 2007, Cell cycle.

[71]  R. Cotter,et al.  Mass Spectrometry , 1992, Bio/Technology.

[72]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Coates,et al.  Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. , 2005, International journal of molecular medicine.

[74]  Xianglin Shi,et al.  AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. , 2007, Cancer research.

[75]  A. Mills.  p63: oncogene or tumor suppressor? , 2006, Current opinion in genetics & development.

[76]  S. T. Kim,et al.  Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members* , 1999, The Journal of Biological Chemistry.

[77]  B. Trink,et al.  p53 associates with and targets ΔNp63 into a protein degradation pathway , 2001 .

[78]  Petra de Graaf,et al.  Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Pietenpol,et al.  The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations , 2003, Molecular and Cellular Biology.

[80]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[81]  A. Fersht,et al.  The Development of a CDK2-Docking Site Peptide that Inhibits p53 and Sensitizes Cells to Death , 2004, Cell cycle.

[82]  Frederick E. Petry,et al.  Principles and Applications , 1997 .

[83]  J. Pietenpol,et al.  Inhibition of Epidermal Growth Factor Receptor Signaling Decreases p63 Expression in Head and Neck Squamous Carcinoma Cells , 2003, The Laryngoscope.

[84]  Suzanne R. Kalb,et al.  Assembly Protein Precursor (pUL80.5 Homolog) of Simian Cytomegalovirus Is Phosphorylated at a Glycogen Synthase Kinase 3 Site and Its Downstream “Priming” Site: Phosphorylation Affects Interactions of Protein with Itself and with Major Capsid Protein , 2004, Journal of Virology.

[85]  J. Pietenpol,et al.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. , 2003, Molecular and cellular biology.

[86]  T. Hupp,et al.  p63: The Phantom of the Tumor Suppressor , 2007, Cell cycle.

[87]  A. Giaccia,et al.  ATR/ATM Targets Are Phosphorylated by ATR in Response to Hypoxia and ATM in Response to Reoxygenation* , 2003, The Journal of Biological Chemistry.

[88]  J. Pietenpol,et al.  ΔNp63α Expression Is Regulated by the Phosphoinositide 3-Kinase Pathway* , 2003, Journal of Biological Chemistry.

[89]  P. Workman,et al.  The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis , 2007, Cell cycle.

[90]  L. Helman,et al.  Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. , 2002, Neoplasia.

[91]  J. Wang-Rodriguez,et al.  STI‐571 (Gleevec) Potentiates the Effect of Cisplatin in Inhibiting the Proliferation of Head and Neck Squamous Cell Carcinoma In Vitro , 2006, The Laryngoscope.

[92]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[93]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.